Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

NCT03228537 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03228537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03228537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 16, 2018
Completion date
September 18, 2027
Enrollment
28 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

biphasic mesothelioma, epithelioid mesothelioma, stage i pleural diffuse malignant mesothelioma ajcc v7, stage ia pleural diffuse malignant mesothelioma ajcc v7, stage ib pleural diffuse malignant mesothelioma ajcc v7, stage ii pleural diffuse malignant mesothelioma ajcc v7, stage iii pleural diffuse malignant mesothelioma ajcc v7